CellGenTech, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
CellGenTech, Inc. - overview
Established
2003
Location
Chiba-shi, -, Japan
Primary Industry
Biotechnology
About
Founded in 2003 and based in Chiba, Japan, CellGenTech, Inc. is a biotechnology company that operates as a developer of drugs for new gene therapy and regenerative medicine. In May 2024, CellGenTech, Inc. raised JPY 300 million in venture funding led by investor FUJIMORI KOGYO CO.
, LTD. The firm as of August 2024, is led by its Directors, Masayoshi, AsoTetsuya MishimaMichihiro, OkaYoshitaka, and Tanaka. CellGenTech focuses on developing advanced gene therapy and regenerative medicine treatments. It specializes in using genetically modified adipocytes (fat cells) for innovative therapies targeting rare and intractable diseases.
CellGenTech's core offerings include treatments for diseases like familial LCAT deficiency and Fabry disease, utilizing its ex-vivo gene therapy platform. The company’s approach involves introducing therapeutic genes into adipocytes to produce necessary proteins or enzymes for treating genetic disorders. The company's Notable achievements include the world’s first clinical study of gene-transduced human fat cells, initiated in 2017, and several successful collaborations with major pharmaceutical firms such as Kyorin Pharmaceutical Co. , Ltd.
, and Fujimori Kogyo Co. , Ltd. The company plans to utilize the May 2024 funding to accelerate the development of its platform offerings.
Current Investors
NISSUI PHARMACEUTICAL CO.,LTD., CareNet Group, FUJIMORI KOGYO CO.,LTD.
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Pharmaceutical Research & Development
Website
www.cellgentech.com
Verticals
HealthTech
Total Amount Raised
Subscriber access only
CellGenTech, Inc. - financials
| Fiscal Year Ended | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 |
|---|---|---|---|---|---|---|
| Revenue (USD) | - | - | - | - | - | - |
| % Revenue Growth (YoY) | - | - | - | - | - | - |
| EBITDA (USD) | - | - | - | - | - | - |
| Operating Income (USD) | - | - | - | - | - | - |
| Operating Margin | - | - | - | - | - | - |
| % EBITDA Margin | - | - | - | - | - | - |
| NET Income (USD) | (180,436,000) | - | (317,417,000) | - | - | - |
| % Net Margin | - | - | - | - | - | - |
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.